FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Finnerty Thomas
2. Issuer Name and Ticker or Trading Symbol

Anika Therapeutics, Inc. [ ANIK ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Human Resources Officer
(Last)          (First)          (Middle)

32 WIGGINS AVENUE
3. Date of Earliest Transaction (MM/DD/YYYY)

2/25/2020
(Street)

BEDFORD, MA 01730
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock (1)2/26/2020  A  3000 A$0 9128 D  
Common Stock 2/26/2020  F  881 (2)D$42.25 (3)8247 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit $0.00 2/25/2020  A   8500     (4) (4)Common Stock 8500 $0 8500 D  

Explanation of Responses:
(1) Reflects the first vesting installment of RSUs granted on February 26, 2019.
(2) Reflects an aggregate of 881 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on February 26, 2020.
(3) Reflects the closing price of the ANIK common stock on February 26, 2020, the trading day on which the vesting of RSUs gave rise to tax withholding obligations.
(4) Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning February 25, 2021.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Finnerty Thomas
32 WIGGINS AVENUE
BEDFORD, MA 01730


Chief Human Resources Officer

Signatures
/s/ Thomas Finnerty2/27/2020
**Signature of Reporting PersonDate

Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more Anika Therapeutics Charts.
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more Anika Therapeutics Charts.